More on Cyclacel Pharmaceuticals earnings

Cyclacel Pharmaceuticals (CYCC) Q2 slips on a per share basis as losses come in higher than anticipated.

Q2 EPS of ($0.10), versus ($0.45) reported last year.

Total revenue of $264K compared to $26K in prior year.

R&D expenses were $2.6M compared to $1.7M for the same period in 2012, primarily due to clinical trial and manufacturing costs.

Cash and cash equivalents totaled $33.7M.

Shares -4.4% AH.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs